Ken Griffin Bristol Myers Squibb CO Transaction History
Citadel Advisors LLC
- $618 Billion
- Q3 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Citadel Advisors LLC holds 2,432,543 shares of BMY stock, worth $114 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
2,432,543
Previous 2,927,800
16.92%
Holding current value
$114 Million
Previous $136 Million
19.05%
% of portfolio
0.02%
Previous 0.02%
Shares
33 transactions
Others Institutions Holding BMY
# of Institutions
2,688Shares Held
1.58BCall Options Held
28MPut Options Held
28.4M-
Vanguard Group Inc Valley Forge, PA196MShares$9.17 Billion0.14% of portfolio
-
Black Rock Inc. New York, NY159MShares$7.43 Billion0.15% of portfolio
-
State Street Corp Boston, MA96.6MShares$4.52 Billion0.16% of portfolio
-
Jpmorgan Chase & CO New York, NY86.2MShares$4.03 Billion0.26% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA73MShares$3.42 Billion0.55% of portfolio
About BRISTOL MYERS SQUIBB CO
- Ticker BMY
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 2,126,160,000
- Market Cap $99.5B
- Description
- Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...